Novartis: Influenza, Human trials

The registry lists 101 Influenza, Human studies with Novartis as lead sponsor. 0 are open to participants now and 48 have results posted.

Phase 1 5Phase 2 48Phase 3 45Phase 4 5No phase 4(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects.CompletedNCT02427750Phase 2Results posted
• Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult SubjectsCompletedNCT02256488Phase 3Results posted
• Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.CompletedNCT02255279Phase 3Results posted
• A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related ComplicationsCompletedNCT01998477Phase 3Results posted
• Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years OldCompletedNCT01992107Phase 3Results posted
• Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and OlderCompletedNCT01992094Phase 3Results posted
• Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 YearsCompletedNCT01928472Phase 1Results posted
• Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and AboveCompletedNCT01885117Phase 3Results posted
• Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and AboveCompletedNCT01880697Phase 3Results posted
• Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and AboveCompletedNCT01879553Phase 2Results posted
• Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of AgeCompletedNCT01879540Phase 2Results posted
• Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and AboveCompletedNCT01867021Phase 4Results posted
• Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of AgeCompletedNCT01857206Phase 3Results posted
• Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.CompletedNCT01855945Phase 1Results posted
• Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in ChildrenCompletedNCT01776554Phase 2Results posted
• Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy AdultsCompletedNCT01776541Phase 2Results posted
• Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly SubjectsCompletedNCT01766921Phase 2Results posted
• Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly SubjectsCompletedNCT01651104Phase 2Results posted
• Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults Aged 18 Years and AboveCompletedNCT01640327Phase 3Results posted
• Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and AboveCompletedNCT01640314Phase 3Results posted
• Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and AboveCompletedNCT01636102Phase 2Results posted
• Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of AgeCompletedNCT01346592Phase 3Results posted
• Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012CompletedNCT01344057Phase 2Results posted
• Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy SubjectsCompletedNCT01342796Phase 2Results posted
• A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or OlderCompletedNCT01222403Phase 4Results posted
• Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of AgeCompletedNCT01209780Phase 3Results posted
• Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly SubjectsCompletedNCT01162122Phase 3Results posted
• Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2010-2011CompletedNCT01152814Phase 2Results posted
• Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 MonthsCompletedNCT00996307Phase 2/3Results posted
• Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)CompletedNCT00973700Phase 3Results posted
• Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly AdultsCompletedNCT00973349Phase 2/3Results posted
• Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)CompletedNCT00972816Phase 2/3Results posted
• Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010CompletedNCT00956761Phase 2Results posted
• Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009CompletedNCT00734734Phase 2Results posted
• Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and AdolescentsCompletedNCT00645411Phase 2/3Results posted
• Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control VaccinesCompletedNCT00644059Phase 3Results posted
• Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult SubjectsCompletedNCT00630331Phase 3Results posted
• Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and AboveCompletedNCT00620815Phase 2Results posted
• Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years OldCompletedNCT00617851Phase 3Results posted
• Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a SubgroupCompletedNCT00579345Phase 3Results posted
• Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical ConditionsCompletedNCT00560066Phase 4Results posted
• Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008CompletedNCT00511914Phase 3Results posted
• Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and ElderlyCompletedNCT00492063Phase 3Results posted
• Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult SubjectsCompletedNCT00481065Phase 2Results posted
• Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years OldCompletedNCT00464672Phase 3Results posted
• Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)CompletedNCT00310804Phase 3Results posted
• Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and ElderlyCompletedNCT00306527Phase 3Results posted
• Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy AdultsCompletedNCT00264576Phase 2Results posted
• Safety and Immunogenicity of One Dose of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture Administered to Adult and Elderly SubjectsCompletedNCT01422512Phase 3
• Safety and Immunogenicity of One Dose of an Inactivated Trivalent Sub-unit Influenza Vaccine Administered to Non-elderly Adult and Elderly SubjectsCompletedNCT01357265Phase 2
• Immunogenicity and Safety of V70P5 Revaccination SubjectsCompletedNCT01210898Phase 3
• Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly SubjectsCompletedNCT01161264Phase 3
• Safety and Immunogenicity of One Dose of Inactivated Trivalent Flu Vaccine Administered to Non-elderly Adult and Elderly SubjectsCompletedNCT01151059Phase 2
• Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011CompletedNCT01147081Phase 3
• Evaluating the Safeness of Trivalent Subunit Inactivated Influenza Vaccines in Preventing Flu on Vietnamese VolunteersCompletedNCT01123954Phase 2
• Drug Use Investigation for Cell-culture Derived Influenza A (H1N1) Emulsion HA VaccineCompletedNCT01098786
• Open-label, Uncontrolled Postmarketing Study of Cell-derived A/H1N1 Influenza HA Vaccine in Japanese Elderly SubjectsCompletedNCT01069367Phase 4
• Observational Safety Study of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived VaccineCompletedNCT01040741
• Observational Study of Safety of Flu Cell Culture Derived Adjuvanted Swine Origin A (H1N1) Pandemic Subunit VaccineCompletedNCT01037855
• Novartis Pandemic Influenza A (H1N1) Vaccine(s) Observational Comparative Safety StudyCompletedNCT01037829
• Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric SubjectsCompletedNCT01000207Phase 2/3
• Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult SubjectsCompletedNCT00996138Phase 2/3
• Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10CompletedNCT00992212Phase 2
• Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of AgeCompletedNCT00971906Phase 3
• Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of AgeCompletedNCT00971542Phase 3
• Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of AgeCompletedNCT00971100Phase 3
• Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of AgeCompletedNCT00970177Phase 3
• Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly SubjectsCompletedNCT00956449Phase 2
• Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010CompletedNCT00945841Phase 3
• Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2009/2010 Recommended in Northern Hemisphere in Non-elderly Adult and in Elderly SubjectsCompletedNCT00918268Phase 2
• Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly SubjectsCompletedNCT00914771Phase 2
• A Dose Ranging Study Comparing Different Combinations of Adjuvanted and Non-adjuvanted Influenza Vaccines in Healthy Children 6 to <36 Months of AgeCompletedNCT00848887Phase 1
• Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination SchedulesCompletedNCT00848029Phase 3
• Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly SubjectsCompletedNCT00841646Phase 2
• Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008/2009CompletedNCT00748813Phase 2
• Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009, When Administered to Non-Elderly Adult and Elderly SubjectsCompletedNCT00748150Phase 2
• Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009CompletedNCT00735410Phase 3
• Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza VaccinesCompletedNCT00735020Phase 1
• Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 MonthsCompletedNCT00649883Phase 2
• Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 StudyCompletedNCT00644540Phase 2
• Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu VaccineCompletedNCT00559975Phase 1
• Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 YearsCompletedNCT00537524Phase 2
• Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to Elderly SubjectsCompletedNCT00522236Phase 2
• Support Annual Strain Update, Safety and Immunogenicity of an Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Subjects 18-64 Years Affected by Chronic Diseases.CompletedNCT00522067Phase 2
• Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic DiseasesCompletedNCT00519064Phase 3
• Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to NON Elderly AND Elderly SubjectsCompletedNCT00518726Phase 2
• Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Formulation 2007-2008CompletedNCT00518453Phase 2
• Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008CompletedNCT00498303Phase 3
• Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza VaccinesCompletedNCT00478816Phase 2
• Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly SubjectsCompletedNCT00434733Phase 3
• Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in ChildrenCompletedNCT00408395Phase 2
• Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in AdultsCompletedNCT00382187Phase 2
• Safety and Immunogenicity of Preservative Free Inactivated Split Influenza Vaccine, Using the Strain Composition 2006/2007 in Non-Elderly Adult and Elderly SubjectsCompletedNCT00354016Phase 3
• Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or OlderWithdrawnNCT00342940Phase 2
• Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or OlderCompletedNCT00329966Phase 2
• Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Elderly SubjectsCompletedNCT00329927Phase 2
• Safety and Immunogenicity of an Adjuvanted Influenza Vaccine in Subjects Aged 65 Years and Over.CompletedNCT00316628Phase 2
• Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects.CompletedNCT00316615Phase 2
• Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly SubjectsCompletedNCT00311480Phase 2
• Safety and Immunogenicity of Three Commercially Available Influenza Vaccines in Children Aged 6 to <36 MonthsCompletedNCT00311428Phase 4